Lonza to sell therapeutic peptides business to PolyPeptide

By Gareth Macdonald contact

- Last updated on GMT

Lonza's peptides facility in Braine-l’Alleud, Belgium (source Google maps)
Lonza's peptides facility in Braine-l’Alleud, Belgium (source Google maps)

Related tags: Chromatography, Peptide synthesis, Protein

Lonza has agreed to sell its therapeutic peptide business to PolyPeptide Laboratories in a deal that will also see the latter firm take on 280 staff.

The deal – financial terms of which were not disclosed – will see Lonza’s peptide development and commercial-scale production facility in Braine-l’Alleud, Belgium change hands.

The takeover is expected to complete in the next few weeks.

A Lonza spokeswoman told us the facility produces therapeutic active pharmaceutical ingredients (APIs) using a variety of methods and technologies - liquid-phase peptide synthesis (LPPS), solid-phase peptide sythesis (SPPS), ligation and cyclization chemistry.

She also confirmed that all 280 Lonza employees at the facility will be joining Malmo, Sweden headquartered PolyPeptide Laboratories.

The Braine-l’Alleud site houses several HPLC (high-performance liquid chromatography) system thin film evaporators, freeze-dryers and a condenser. It also has a research and development lab and offices dedicated to logistics, procurement, HR, finance.

The Swiss firm described the unit as a niche business and said the divestiture will “streamline” its pharma and biotech segment.

Lonza stressed that operations at Braine-l’Alleud will not be impacted by the deal. 

Lonza paid former owner UCB €120m ($128m) for the site in 2006.

Polypeptide director Peter Nilsson told us "our aim is to get access to the large scale production capacity for customers in our current development portfolio and to continue to serve the existing customers of the facility.​"

Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more